ContraFect Reports Second Quarter 2020 Financial Results and Provides Business Update August 14, 2020
ContraFect Announces up to $18.9 Million in Funding from CARB-X to Support Acceleration of the CF-370 Program for Treating Pseudomonas aeruginosa Infections towards Clinical Stage Development July 20, 2020
Contrafect Announces Publication of Exebacase Phase 2 Study Results in the Journal of Clinical Investigation June 17, 2020
ContraFect Corporation Announces Private Placement of Common Stock and Warrants to Pfizer Inc. May 26, 2020
ContraFect Corporation Prices Approximately $52.5 Million Public Offering of Common Stock and Warrants May 21, 2020
